Neuromuscular Monitoring of Rocuronium 0.6 mg/kg in Children Aged 3–24 Months With Electromyography and Acceleromyography: An Observational Study - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Assessment of Neuromuscular Function Following Rocuronium Administration (0.6 mg/kg) in Pediatric Patients Aged 3 to 24 Months Using Electromyography and Acceleromyography: An Observational Analysis

  • By

  • Sarah Sofie Wadland

  • Karl Peter Damgård Madsen

  • Mikkel Helmuth Jensen

  • Magnus Fuhr Hovind

  • Morten Sonne

  • Morten Bøttger

  • Arash Afshari

  • Frederik Mondrup

  • Matias Vested

  • May 19, 2026

Share

  • 1

    The study assessed neuromuscular function in pediatric patients aged 3 to 24 months after administering rocuronium 0.6 mg/kg.

  • 2

    Objective neuromuscular monitoring was performed using electromyography (EMG) and acceleromyography (AMG) at the tibial or ulnar nerve.

  • 3

    The primary outcome was the time to train-of-four ratio (TOFR) ≥ 0.9, indicating recovery from neuromuscular block.

  • 4

    The study included 100 patients, with monitoring conducted simultaneously at both the tibial and ulnar nerves.

  • 5

    Informed consent was obtained from parents or guardians, and the study was approved by relevant ethical committees.

Original Source(s)

Neuromuscular Monitoring of Rocuronium 0.6 mg/kg in Children Aged 3–24 Months With Electromyography and Acceleromyography: An Observational Study

  • by Sarah Sofie Wadland, Karl Peter Damgård Madsen, Mikkel Helmuth Jensen, Magnus Fuhr Hovind, Morten Sonne, Morten Bøttger, Arash Afshari, Frederik Mondrup, Matias Vested

  • May 19, 2026

Related Content

Risk of Injury Among Children and Youths Whose Mothers Experienced Violent Injury: A Systematic Review and

Refreshing the paediatric emergency medicine research priorities across the UK and Ireland

Further Reflections on Metabolically Healthy Obesity in Children